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INTRODUCTION
Clinical practice guidelines are considered 
the gold standard for disease 
management and treatment. Industry 
payments to guideline authors may 
influence their clinical recommendations, 
potentially resulting in medical and/or 
financial consequences to patients. 
OBJECTIVES
Our team of investigators sought to 
determine to what extend Endocrine 
Society guideline authors receive and 
properly report financial conflicts of 
interest from industry payments in 
adherence to the Physician Payments 
Sunshine Provision of the Affordable Care 
Act. 
METHODS
Study Design: A cross-sectional analysis of 
all clinical practice guidelines published by 
the Endocrine Society since the Sunshine 
Provision mandate. Our primary outcome 
was the number of authors receiving 
payments from industry, stratified by 
amount thresholds. Secondary outcome 
measure was the number of authors with 
accurate conflict of interest disclosure 
statements. 
We searched the Endocrine Society’s 
website for clinical practice guidelines 
published between January 2014 and 
December 2017. Identified guideline 
authors were independently searched by 
two investigators on the Open Payments 
Database. Received payments were 
extracted and statistically analyzed 
(excluding food/beverage payments). 
Payments were cross-referenced with 
corresponding author disclosure 
statements. 
CONCLUSION
Industry payments among 
Endocrine Society clinical practice 
guideline authors were 
widespread, with several exceeding 
$250,000. Nearly half of author 
disclosure statements were 
inaccurate. The Endocrine Society’s 
disclosure policy should be more 
strictly enforced for future 
guideline authors. 
RESULTS
Guideline Authors who Received Payment(s) from Industry 
Percentage (%) of Authors who Received ≥ 1 
Payments from Industry
Clinical Practice Guideline Author Payments
Discrepant Guideline Author COI Disclosures
≥ $1,000 ≥ $10,000 ≥ $50,000
≥ $100,000 ≥ $250,000
Guideline Title 
(No. of Authors)
No. (%) of Authors
Timeframe for Which Data was 
IncludedReceiving 
Payment
Receiving 
≥ $1,000
Receiving 
≥ $50,000
Receiving 
≥ $100,000
Receiving 
≥ $250,000
Functional Hypothalamic Amenorrhea (9) 5 (56) 5 (56) 1 (11) 0 (0) 0 (0) Jan 2016 to Dec 2017
Pediatric Obesity: Assessment, Treatment, & Prevention (7) 2 (29) 2 (29) 2 (29) 2 (29) 1 (14) Jan 2016 to Dec 2017
Diagnosis & Treatment of Primary Adrenal Insufficiency (11) 1 (9) 1 (9) 0 (0) 0 (0) 0 (0) Jan 2015 to Dec 2017
Diabetes Technology: Continuous Subcutaneous Insulin 
Infusion Therapy & Continuous Glucose (8) 5 (63) 5 (63) 4 (50) 4 (50) 4 (50) Jan 2015 to Dec 2017
Hormonal Replacement in Hypopituitarism in Adults (7) 3 (43) 3 (43) 3 (43) 3 (43) 3 (43)* Jan 2015 to Dec 2017
Treatment of Cushing’s Syndrome (7) 3 (43) 3 (43) 1 (14) 1 (14) 1 (14) Jan 2014 to Dec 2016
Treatment of Symptoms of the Menopause (7) 3 (43) 2 (29) 2 (29) 1 (14) 1 (14) Jan 2014 to Dec 2016
Pharmacological Management of Obesity (8) 5 (63) 5 (63) 4 (50) 4 (50) 3 (38) Jan 2014 to Dec 2016
Paget’s Disease of Bone (7) 3 (43) 3 (43) 1 (14) 1 (14) 1 (14) Jan 2013 to Dec 2015
Androgen Therapy in Women (8) 3 (38) 3 (38) 3 (38) 2 (25) 0 (0) Jan 2013 to Dec 2015
Acromegaly (7) 3 (43) 3 (43) 3 (43) 3 (43) 3 (43)* Jan 2013 to Dec 2015
Guideline Title (No. of Authors)
No. (%) of Authors
Total Non-Disclosed 
Payments per 
Author, Median 
(IQR), $
Receiving 
Payment
Receiving 
Payment with 
Discrepant COI 
Disclosures
Functional Hypothalamic 
Amenorrhea (9) 5 (56) 2 (40)
7,461 
(7,070-7,851)
Pediatric Obesity: Assessment, 
Treatment, & Prevention (7) 2 (29) 2(100) 
42,448 
(37,068-47,828)
Diagnosis & Treatment of Primary 
Adrenal Insufficiency (11) 1 (9) 0 (0)
0 
(0)
Diabetes Technology: Continuous 
Subcutaneous Insulin Infusion 
Therapy & Continuous Glucose (8) 
5 (63) 5 (100) 67,189 (17,773-203,898)
Hormonal Replacement in 
Hypopituitarism in Adults (7)  3 (43) 3 (100)
76,788 
(64,896-4000,753)
Treatment of Cushing’s Syndrome (7) 3 (43) 3 (100) 2,173 (2,118-8,519)
Treatment of Symptoms of the 
Menopause (7) 3 (43) 1 (33)
564 
(0)
Pharmacological Management of 
Obesity (8) 5 (63) 4 (80)
17,512 
(5,447-175,407)
Paget’s Disease of Bone (7) 3 (43) 3 (100) 2,798 (2,594-6,410)
Androgen Therapy in Women (8) 3 (38) 3 (100) 116,740 (89,719-127,463)
Acromegaly (7) 3 (43) 2 (67) 58,776 (52,116-65,436)
Table 1: 11 of the 14 clinical practice guidelines published by the Endocrine Society had ≥ 1 author who received payment from industry. Of those 11 clinical practice guidelines, 57 authors 
were evaluable, with 34 (60%) receiving ≥ 1 payment from industry. Monetary data was included the year prior, publication year, and year following clinical practice guideline publication, 
when available. 
* The same author published 2 guidelines and received ≥ $250,000 in payment from industry during the corresponding timeframe for each guideline. The author contributed as 1 in the 
denominator for all appropriate author percentage calculations. 
Figure 1: Percentage of Clinical Practice Guideline authors 
broken down into stratified total payments from industry. 
Table 2: Of the 11 Clinical Practice Guidelines in which ≥ 
1 author received industry payment, 27 (47%) financial 
disclosure statements were inaccurate. Median 
inaccurate disclosure payment was $28,524 (IQR $5,714-
94,418), with a payment total of $2,870,485.27. 
Figure 2: Of the 34 authors who received ≥ 1 payment from industry, the 
median general payment (minus food & beverage) was $18,169 ($3,326-
99,076), median associated research payment of $94,910 ($0-338,928), and 
median total payment (minus food & beverage) of $212,362 ($19,150-
480,230) per clinical practice guideline author. Cumulative total of all 
payments (minus food & beverage) was $14,834,661 with a maximum of 
$3,758,021 for a single author. 
